These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 9516088)

  • 41. Effect of bcr-abl oligodeoxynucleotides on the clonogenic growth of chronic myelogenous leukaemia cells.
    de Fabritiis P; Skorski T; De Propris MS; Paggi MG; Nieborowska-Skorska M; Lisci A; Buffolino S; Campbell K; Geiser T; Calabretta B
    Leukemia; 1997 Jun; 11(6):811-9. PubMed ID: 9177433
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Highly efficient elimination of Philadelphia leukemic cells by exposure to bcr/abl antisense oligodeoxynucleotides combined with mafosfamide.
    Skorski T; Nieborowska-Skorska M; Barletta C; Malaguarnera L; Szcyzlik C; Chen ST; Lange B; Calabretta B
    J Clin Invest; 1993 Jul; 92(1):194-202. PubMed ID: 8325984
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The influence of target protein half-life on the effectiveness of antisense oligonucleotide analog-mediated biologic responses.
    Spiller DG; Giles RV; Broughton CM; Grzybowski J; Ruddell CJ; Tidd DM; Clark RE
    Antisense Nucleic Acid Drug Dev; 1998 Aug; 8(4):281-93. PubMed ID: 9743466
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The role of molecular techniques in the clinical management of leukemia. Lessons from the Philadelphia chromosome.
    Westbrook CA
    Cancer; 1992 Sep; 70(6 Suppl):1695-700. PubMed ID: 1516023
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Negative regulation of p120GAP GTPase promoting activity by p210bcr/abl: implication for RAS-dependent Philadelphia chromosome positive cell growth.
    Skorski T; Kanakaraj P; Ku DH; Nieborowska-Skorska M; Canaani E; Zon G; Perussia B; Calabretta B
    J Exp Med; 1994 Jun; 179(6):1855-65. PubMed ID: 8195713
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Oncogene-targeted antisense oligodeoxynucleotides combined with chemotherapy or immunotherapy: a new approach for tumor treatment?
    Nieborowska-Skórska M; Nakashima M; Ratajczak M; Steplewski Z; Calabretta B; Skórski T
    Folia Histochem Cytobiol; 1994; 32(1):35-40. PubMed ID: 8026602
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Molecular pathogenesis of chronic myeloid leukemia: implications for new therapeutic strategies.
    Warmuth M; Danhauser-Riedl S; Hallek M
    Ann Hematol; 1999 Feb; 78(2):49-64. PubMed ID: 10089019
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Autologous bone marrow transplantation for patients with chronic myelogenous leukemia after in vitro purging of the graft with bcr/abl antisense oligodeoxynucleotides].
    Sun J; Wu B; Liu Q; Feng R; Liu X; Meng F; Zhou S
    Zhonghua Xue Ye Xue Za Zhi; 2000 Aug; 21(8):400-2. PubMed ID: 11877009
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Molecular basis of chronic granulocytic leukemia: from test-tube to patient].
    Skórski T
    Acta Haematol Pol; 1994; 25(2 Suppl 1):184-91. PubMed ID: 8067203
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antisense therapeutics in chronic myeloid leukaemia: the promise, the progress and the problems.
    Clark RE
    Leukemia; 2000 Mar; 14(3):347-55. PubMed ID: 10720125
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Development of knowledge-based therapy for cancer: identification of unique targets.
    Rao SG
    Natl Med J India; 1998; 11(6):301-2. PubMed ID: 10083808
    [No Abstract]   [Full Text] [Related]  

  • 52. Antisense oligonucleotides as therapeutics for malignant diseases.
    Ho PT; Parkinson DR
    Semin Oncol; 1997 Apr; 24(2):187-202. PubMed ID: 9129689
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antisense strategy in hematological malignancies.
    Warzocha K
    Cytokines Cell Mol Ther; 1999 Mar; 5(1):15-23. PubMed ID: 10390076
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Oligonucleotides in the treatment of leukemia.
    Bayever E; Iversen P
    Hematol Oncol; 1994; 12(1):9-14. PubMed ID: 8194842
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Antisense oligonucleotides as therapeutic agents.
    Alama A; Barbieri F; Cagnoli M; Schettini G
    Pharmacol Res; 1997 Sep; 36(3):171-8. PubMed ID: 9367660
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Capping of bcr-abl antisense oligonucleotides enhances antiproliferative activity against chronic myeloid leukemia cell lines.
    Thomas M; Kosciolek B; Wang N; Rowley P
    Leuk Res; 1994 Jun; 18(6):401-8. PubMed ID: 8207957
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Oligonucleotide N3'-->P5' phosphoramidates as antisense agents.
    Gryaznov S; Skorski T; Cucco C; Nieborowska-Skorska M; Chiu CY; Lloyd D; Chen JK; Koziolkiewicz M; Calabretta B
    Nucleic Acids Res; 1996 Apr; 24(8):1508-14. PubMed ID: 8628685
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prospects for gene-directed therapy with antisense oligodeoxynucleotides.
    Calabretta B; Skorski T; Szczylik C; Zon G
    Cancer Treat Rev; 1993 Apr; 19(2):169-79. PubMed ID: 8481928
    [No Abstract]   [Full Text] [Related]  

  • 59. Progress in antisense oligonucleotide therapeutics.
    Crooke ST; Bennett CF
    Annu Rev Pharmacol Toxicol; 1996; 36():107-29. PubMed ID: 8725384
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Management of chronic myeloid leukemia: targets for molecular therapy.
    Barnes DJ; Melo JV
    Semin Hematol; 2003 Jan; 40(1):34-49. PubMed ID: 12563610
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.